Compare AIRE & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | CLNN |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 48.4M |
| IPO Year | 2023 | N/A |
| Metric | AIRE | CLNN |
|---|---|---|
| Price | $0.28 | $5.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.3M | 60.3K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $948,420.00 | N/A |
| Revenue This Year | $470.21 | N/A |
| Revenue Next Year | $143.58 | $82.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $2.28 |
| 52 Week High | $1.55 | $13.50 |
| Indicator | AIRE | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 31.57 | 56.65 |
| Support Level | $0.14 | $3.54 |
| Resistance Level | $0.35 | $5.71 |
| Average True Range (ATR) | 0.02 | 0.47 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 6.80 | 85.13 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.